Research programme: therapeutic antibodies and proteins - Keel Pharmaceuticals/Organon
Latest Information Update: 20 Aug 2009
At a glance
- Originator Keel Pharmaceuticals; Organon Pharmaceuticals USA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 21 Nov 2005 Preclinical trials in Undefined in USA (unspecified route)